.png){kind=icon}
.png){kind=icon}
Return
Systemic Mastocytosis, Version 2.2019
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2018.0088.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.
Keywords:
MAST-CELL ACTIVATION
KIT D816V MUTATION
HYMENOPTERA VENOM ALLERGY
BASAL SERUM TRYPTASE
INTERFERON-ALPHA
SPANISH NETWORK
C-KIT
RISK-FACTORS
PHASE-II
CLINICOPATHOLOGICAL FEATURES
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations